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Background: Diagnosis of severe peanut allergy is difficult and delays in making an accurate diagnosis may place
the patient at risk. Adults with a history of anaphylaxis must strictly avoid any contact with peanuts or products that
may contain traces of peanuts. For these persons, conventional evaluations with skin prick testing (SPT) and IgE
tests may not be sufficient to assess the risk of anaphylaxis. Therefore, we investigated whether the basophil activation
test (BAT) could be used for the diagnosis of severe peanut allergy in adults. We compared the non-invasive BAT with
conventional laboratory diagnostic tests, including SPT and specific IgE to allergen extracts and components, for
the diagnosis of severe peanut allergy.
Methods: Forty-seven persons with severe allergy to peanuts and a clinical diagnosis of anaphylaxis (PA-group),
22 subjects with peanut sensitization (PS-group) and 22 control (C-group) subjects, all in the age range of 18–60
years, were recruited retrospectively and prospectively into the study. Thirty-four patients with peanut allergy and
11 peanut-sensitized patients were sensitized to soy, while 36 patients in the PA-group and 20 patients in the
PS-group were sensitized to birch pollen. All the patients and control subjects were investigated with BAT and
SPT for responses to peanut, soy and birch extracts and their serum samples were assayed for the presence of
specific IgE to peanut, soy and birch extracts, as well as IgE to allergen components (ISAC).
Results: In a multivariate factor analysis, severe peanut allergy (PA) was positively associated with SPT to peanut,
IgE to peanut, BAT to peanut and IgE to rAra h 1, 2, 3 and 6 peanut components, as well as to soy components
(nGly m 5 and nGly m 6). In contrast, peanut sensitization was positively associated with increased levels of IgE to
rAra h 8, birch and birch-related components. BAT-detected reactivity to peanut was significantly higher in patients who
had a history of severe allergy to peanuts, as compared with patients who were sensitized to peanuts (p < 0.001), and the
receiver operating curve (ROC) analysis showed that BAT had high sensitivity and specificity for predicting severe peanut
allergy, with a ROC area under the curve of 0.862. However, in the PA-group, the BAT results for peanut correlated only
weakly with the levels of IgE to rAra h 1, 2 and 3 and nAra h 6. Study limitations: oral provocation in the patients with a
history of severe peanut allergy could not be performed to compare clinical reactivity with the BAT result due to ethical
constraints. Neither was it possible to perform BAT with peanut recombinant allergens which were not available at the
time the study commenced
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Conclusions: BAT is useful in determining the severity of peanut allergy and may be used as a complementary
diagnostic tool to ensure accurate diagnosis of severe peanut allergy in adults. Thus, it may reduce the need to
subject these patients to further tests, including an open challenge with peanuts.
Keywords: Peanut allergy, Basophil activation test, Allergen componentsBackground
Peanut allergy is one of the most common food aller-
gies among children and shows increasing prevalence
in adults [1–5]. The conventional tests for diagnosing
peanut allergy are not adequate to predict the severity
of the allergy, which means that they are not optimal
for the correct diagnosis of asymptomatic patients who
are sensitized to peanuts [3, 4]. Accurate clinical assess-
ment requires further investigation with an oral food
challenge, which may not be desirable for safety reasons
[6]. The lack of accurate diagnostic tools may lead to
incorrect or misleading diagnoses, with consequent im-
paired quality of life for the patient [7]. Although most
food allergies become less severe or resolve entirely
during adulthood, the skin prick and/or IgE-tests con-
tinue to give positive results for some of these patients.
In some regions, such as Central and Northern Europe,
the diagnostic issues related to peanut allergy are even
more complex due to the cross-reaction with birch
pollen [8]. A person who is allergic to birch pollen may
develop a secondary peanut allergy, which may be
interpreted as a true primary peanut allergy [9]. More-
over, individuals who are sensitized to peanuts may de-
velop secondary allergies to other legumes, e.g., soy
bean and vice versa [10–12].
Some years ago, a complementary diagnostic tool
(microarray technique) was introduced that determines
the sensitization profile with the help of allergen compo-
nents [13, 14], and this has been used mainly to resolve
sensitization patterns in food allergy. Through the use of
the peanut allergen components Ara h 1, 2, 3, 6, 8 and 9,
the differential diagnosis of true clinical peanut allergy has
improved [15, 16]. However, while the pattern of
sensitization to the different peanut allergens may predict
that the patient is going to react to peanuts, it cannot pre-
dict the severity of the reaction [17]. The profile of
sensitization to recombinant allergens provides additional
help in understanding the cross-reactivity patterns of dif-
ferent allergens e.g. legumes, albeit without ascertaining
whether this cross-reactivity has any clinical relevance.
A relatively new and promising diagnostic tool, the baso-
phil activation test (BAT) [18], has been applied recently
for the diagnosis of various allergies; initially, BAT was used
mainly for the diagnosis of food allergies in children
[19–23]. The BAT has also gained attention because it
seems to show a good correlation with true orpersistent peanut allergy in children [24]. Whether the
reactivity measured by BAT correlates with asymptom-
atic sensitization or persistent clinical allergy in adults
remains to be elucidated. Similarly, only limited infor-
mation is available on whether the BAT correlates with
the outcome of an oral food challenge [25]. Interest-
ingly, the BAT was used in a recent study to monitor
tolerance induction in children who underwent oral
immunotherapy with egg [26], and basophil histamine
release has been used to monitor the effectiveness of
anti-IgE (omalizumab) treatment administered prior to
an oral immunotherapy regime in patients with severe
peanut allergy [27].
The aim of the presents study was to investigate whether
patients who have suffered a severe allergic reaction to pea-
nuts or who have been designated as being allergic to pea-
nuts since childhood, can be diagnosed with clinical or
persistent peanut allergy using the BAT. We also examined
whether the BAT could discriminate between patients with
severe peanut allergy and sensitized patients with no or
mild symptoms in order to evaluate if a person is no longer
severely allergic to peanut even when displaying persistent
IgE-mediated peanut sensitivity, as assessed using conven-
tional tests, including reactivities to allergen components.
In addition, we asked if the BAT can be used for the diag-
nosis of co-existent concomitant allergy to soy in patients
who are sensitized or allergic to peanuts and if any possible
underlying clinical cross-reactivity among legumes can be
revealed by combining BAT reactivity and IgE sensitization
profiling to allergen components.
Materials and methods
Study population
Forty-seven adults with severe allergy to peanuts
(PA-group), 22 peanut-sensitized persons (PS-group)
and 22 healthy controls (C-group), all in the age range
of 18–60 years, were recruited either retrospectively or
prospectively to the study between January and Decem-
ber of 2013. All the patients had been referred to the
Allergy Clinic at the Sahlgrenska University Hospital in
Gothenburg for allergy investigation. The PA-group
consisted of patients with severe peanut allergy who
had a convincing history of anaphylaxis to peanuts with
objective symptoms, together with the routine allergo-
logical investigation including a detailed clinical history
and/or IgE titers to rAra h 2 > 0.35 kU/L. The PS-group
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vestigations with oral peanut challenge for suspected
peanut allergy due to a co-existing allergy to birch
pollen. The majority of the patients in the PA-group
and PS-group were also sensitized to soy and/or birch
pollen. The profiles of the participants, including the
clinical diagnosis, grade of reaction to peanut and pea-
nut avoidance, are presented in Table 1. The non-
allergic control subjects were recruited among the staff
at the Sahlgrenska University Hospital or their relatives
and friends. There were no drop-outs during the study.
All patients and controls were investigated using the
SPT for peanut, soy and birch, as well as measurements
of total IgE and specific IgE for peanut, soy and birch.
Blood was collected from each subject for the BAT and
serum was saved for analysis of sensitization to allergen
components (ISAC). Exclusion criteria for all the sub-
jects were: pregnancy; lactation; rheumatic or systemic
disease; and immune deficiency. Five patients in the
PA-group and three in the PS-group had previous or
currently ongoing treatment with immunotherapy for
pollen allergy (birch and grass allergy). All the patients
in the PS-group answered a questionnaire regarding
whether they had eaten peanuts after they had under-
gone a negative open oral challenge with peanut.
All the allergic patients were taking intermittent medi-
cations, such as anti-histamines, nasally administered
corticosteroids and eye-drops during the pollen season.
Patients with asthma used inhaled corticosteroids and
beta-mimetics as required. None of the patients required
medication with oral or injected corticosteroids during
the period of the study.Table 1 Clinical and demographic features of the patient
groups included in the study (PA=peanut allergic patients,
PS=peanut sensitized patients, C=healthy controls)
PA (n = 47) PS (n = 22) C (n = 22)
Men 25 7 5
Women 22 15 11
Age (mean) 25 28 33
Sensitization to peanut (sIgE) 47 20 -
Sensitization to peanut (SPT) 47 18 -
Sensitization to birch (sIgE) 36 20 -
Sensitization to birch (SPT) 34 18 -
Sensitization to soy (IgE) 34 11 -
Sensitization to soy (SPT) 19 13 -
Asthma 31 11 -
Immunotherapy (birch pollen) 5 3 -
Open peanut challenge during
allergy investigation
8 22 -
Peanut avoidance 47 7 -
Soy avoidance 19 5 -This study was approved by the Ethics Committee of
the Regional Ethical Review Board in Gothenburg (Dnr.
591-10). Written informed consent was obtained from
both the patients and control subjects.
Allergy assessments
Skin prick test (SPT)
The skin prick test was performed using allergen ex-
tracts from peanut, soy and birch (Soluprick, ALK-
Abelló, Hørsholm, Denmark). Histamine (10 mg/ml) and
vehicle were used as references. The SPT was considered
positive when the wheal reaction diameter was ≥3 mm.
A wheal reaction equivalent in diameter to that of the
histamine reference was recorded as 3+, while one that
was half of the diameter of the histamine reaction was
recorded as 2+. If the wheal diameter was twice that of
the histamine reference it was recorded as 4+, whereas
one that was four times that of the reference was re-
corded as 5+ etc.
ImmunoCAP
The serum levels of total IgE and specific IgE antibodies
to peanut (f13), soy (f14), and birch-pollen allergen ex-
tracts (t3) were measured using ImmunoCAP (Thermo-
fisher Scientific, Uppsala, Sweden).
ISAC
IgE against allergen components was measured using a
micro-array Immunoassay/ImmunoCap (ISAC; Thermo-
fisher Scientific, Uppsala, Sweden), which covers 112
components from 51 sources of allergens. The results
are expressed as ISAC Standardized Units (ISU) with a
threshold of >0.3 ISU. The ISAC analysis was performed
as recommended by the manufacturer.
Open challenge
All the patients in the PS-group underwent an open
challenge with peanut and showed a negative outcome
before they were included in the study. The open chal-
lenges were performed as part of the investigation ac-
cording to EAACI position paper and the total dose of
peanut used for the open challenge was 10 g [5].
Allergen extracts used for the basophil activation test
The allergen extracts used in this study were: peanut
(Arachis hypogaea, protein concentration 6 mg/ml); soy
(Glycine max, protein concentration of 1.9 mg/ml); and
birch (Betula verrucosa, protein concentration of0.08
mg/ml) (Soluprick, ALK-Abelló, Hørsholm, Denmark). For
the BAT, the allergen extracts were serially diluted in
10-fold steps from an initial 1/30 dilution of the Solu-
prick extract. The peanut extract was tested in 12 serial
10-fold dilutions and the soy and birch extracts were
tested in five serial 10-fold dilutions. For the serum
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with additional dilutions.
Basophil activation test
Basophil activation was measured based on the up-
regulation of CD63 on CD203c + basophils observed in
flow cytometry of blood samples collected in heparinized
tubes. All the tests were carried out within 4 h of blood
sampling. To study the activation of basophils, the Baso-
FlowEx® Kit (EXBIO, Prague, Czech Republic) was used
according to the manufacturer’s recommendations. Briefly,
100 μl of heparinized whole blood and 50 μl of Stimula-
tion Buffer were added to all the tubes. Subsequently, 5 μl
of allergen solution (allergen extracts for peanut, soy and
birch; Soluprick) were added to the samples. For the posi-
tive control, 10 μl of Stimulation Control [a cross-linking
anti-IgE antibody mixed with a stimulating peptide,
N-formyl-Met-Leu-Phe (fMLP)] was added. The tubes
were gently vortexed and incubated at 37 °C for
15 min in a water bath, followed by mixing with 20 μl
of Staining Reagent, which contained anti-CD63 FITC
and anti-CD203c PE antibodies. After further incuba-
tion for 20 min on ice, 300 μl of Lysing Solution were
added and the tubes were re-incubated for 5 min at
room temperature, followed by the addition of 4 ml of
de-ionized water for 10 min. After centrifugation at
300 × g for 5 min, the supernatant fluid was removed
and the pelleted cells were re-suspended in 0.4 ml
PBS. Samples were analyzed in the BD FACSCanto II
flow cytometer. The gate for the basophil population
(CD203c positive, SSC low) was set as shown in Fig. 3.
Using the negative control sample, the gate for non-
stimulated basophils (CD63 low) was set as shown in
Fig. 3d. Basophils in Q2 were considered to be acti-
vated. The cut-off for determining a positive test was
set at 15 % CD63-positive basophils, in line with the
manufacturer’s instructions. The gates were the same
for all the tests conducted on an individual patient,
although they were positioned individually for each
patient. The level of basophil activation is expressed
as %CD63+ basophils above the threshold set in the
negative control. Approximately 600 basophils were
acquired for each analysis (Fig. 3d and e).
Statistical analyses
The statistical analyses were carried out using the IBM
SPSS Statistics 22.0 software. The values shown repre-
sent individual data-points or means and median
values. For each patient, the basophil allergen thresh-
old sensitivity was calculated as the lowest allergen
concentration that was able to activate 50 % of the ba-
sophils that were activated in the stimulation control
(BAT AC50). The BAT AC50-value was calculated
using a linear interpolation of the response to theallergen and is presented as the log10 value of the dilution
factor, i.e., the higher the number the more sensitive is the
patient. Data for BAT are reported as medians with inter-
quartile ranges (IQR). Mann-Whitney U-tests were used
for statistical comparisons of the groups of patients.
Correlations between different parameters within the
same group were evaluated by Spearman’s correlation
coefficient. The complete results of the most relevant
and influential statistical correlations between the vari-
ables in PA-group and the PS-group obtained in the
study are provided in Additional file 1: Table S3 and
Additional file 2: Table S4.
Logistic regression analysis was performed to determine
whether covariate diagnostic variables could be combined
with the BAT results to achieve a more accurate diagnosis.
All tests were two-tailed and the level of significance was
set at p < 0.05. Receiver operating characteristics (ROC)
curve analysis was performed to calculate the optimal cut-
off value of AC50 that corresponded to the highest specifi-
city and sensitivity. Multivariate factor analysis (SIMCA-P+
software; Umetrics, Umeå, Sweden) was used to examine
the relationships between individuals with severe peanut al-
lergy or subjects sensitized to peanut (Y-variables) and the
various parameters studied (X-variables). Projection to
latent structures discriminant analysis (PLS-DA) was imple-
mented to examine whether allergic individuals compared
with sensitized and control individuals could be discrimi-
nated based on the X-variables examined. Orthogonal par-
tial least-squares discriminant analysis (OPLS-DA) was
performed to correlate Y-variables and X-variables to each
other in linear multivariate models. Variable influence on
projection (VIP) values can be used to discriminate be-
tween important and unimportant predictors for the model.
The OPLS-DA plot of the results (Fig. 1b) is based on
X-variables with variable influences on projection values
(VIP-values) ≥0.83 and the OPLS column loading plot in
Fig. 2a is based on VIP-values ≥0.88. In the OPLS ana-
lyses, the relative importance of each X-variable to the
Y-variable is represented by column bars. The larger
the bar and smaller the error bar and the stronger and
more certain is the contribution to the model. The




The demographic and clinical characteristics of the
patients and control subjects are shown in Table 1.
Three patients in the PA-group and one patient in the PS-
group who showed spontaneous stimulation of >10 %
of their basophils in the negative control were excluded
from the study. One patient in the PA-group was found
to be a non-responder in the positive control of the
BAT and was excluded from the study. Three healthy
AB
Fig. 1 a PLS-discriminant analysis score scatter plot showing the distinction of patients with severe allergy to peanuts (black dots, n = 47) from
patients sensitized to peanuts (green diamonds, n = 22). All the healthy controls are clustered in the lower-left quadrant (red triangles, n = 22).
b OPLS-discriminant analysis column loadings plot depicting the associations between patients with severe allergy to peanuts and patients sensitized
to peanuts. The X-variables represented by a bar pointing in the same direction as severe allergy to peanuts (located to the far left) are
positively associated. The OPLS-DA column plot is based on X-variables with VIP-values ≥0.83. R2Y indicates how well the variation of Y is
explained, while Q2 indicates how well Y can be predicted
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15 % of the level in the positive control but were still
included in the study. In contrast, three patients in the
PA-group and five patients in the PS-group were non-
responders to peanut with less than 15 % of their
basophils responding. Furthermore, 7/22 (32 %) peanut-
sensitized subjects who had shown a negative open
challenge test still avoided peanuts and 19/47 (42 %)
patients with severe allergy to peanut avoided soy
(Table 1).Peanut allergy can be distinguished from peanut
sensitization in a multiple regression model that includes
conventional tests and BAT to peanut
Initially, we investigated whether patients with severe
allergy to peanuts (PA-group), patients sensitized
to peanuts (PS-group) and healthy control subjects
(C-group) could be discriminated based on X-variables
that included the SPT (to peanut, soy and birch), total
and specific (ISAC) IgE levels and basophil activation.




Fig. 2 (See legend on next page.)
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Fig. 2 a OPLS column-loading plot showing the X-variables that are most strongly associated with the BAT AC50-value for peanut within the PA-group.
X-variables represented by a bar pointing in the same direction as AC50 peanut (located to the far left) are positively associated, whereas variables in the
opposite direction are inversely related. The OPLS plot is based on X-variables with VIP-values ≥0.88. R2Y indicates how well the variation of Y is explained,
while Q2 indicates how well Y can be predicted. The univariate correlations between the variables most strongly associated with BAT AC50P
in the PA-group are illustrated for: rAra h 1 (r= 0.314, p= 0.032) (b); BAT AC50 soy (r= 0.413, p= 0.04) (c); and IgE to peanut (r= 0.235, p= 0.112) (d). In the
PS-group, the univariate correlations between rAra h 8 are illustrated for: BAT AC50P (r= 0.479, p= 0.024) (e); rGly m 4 (r= 0.757, p< 0.001) (f); and rBet v 1
(r= 0.676, p= 0.001) (g). PA, patients with severe peanut allergy; PS, peanut-sensitized patients
Rentzos et al. Clinical and Translational Allergy  (2015) 5:22 Page 7 of 14PA-group and PS-group (Fig. 1a). The majority of the
PA patients appeared in the lower-right quadrant, while
the PS patients were plotted in the upper-left quadrant.
All the healthy controls were tightly clustered in the
lower-left quadrant (Fig. 1a). Five individuals were lo-
cated outside the ellipse, due to variability or missing
data for one or more X-variables, compared to the
other observations.
The X-variables that displayed the strongest relation-
ship (positive or negative) to the PA and PS subjects,
respectively, were identified in the OPLS-DA column
plot (Fig. 1b). The model is based on X-variables with
VIP-values ≥0.83. The VIP column plot for all X-variables
assessed is shown in Additional file 3: Figure S1.
X-variables represented by a bar pointing in the same
direction as PA are positively associated, whereas
X-variables pointing in the opposite direction are re-
lated to PS. Severe allergy to peanuts was positively
associated with SPT to peanut, specific IgE to peanut,
BAT AC50 to peanut and Ara h components 1, 2, 3
and 6 (Fig. 1b). Positively associated with being sensi-
tized to peanut were specific IgE to birch and rAra h 8,
along with other birch homolog variables (PR10-proteins)
(Fig. 1b). Thus, these results indicate that patients with al-
lergy to peanuts and patients sensitized to peanuts differ
with respect to the magnitudes of their responses in con-
ventional laboratory tests, as well as in the BAT to peanut.
Therefore, the BAT in combination with all relevant vari-
ables might be useful for identifying cases of severe peanut
allergy.
Among all X-variables examined, the variables most
strongly positively associated with the BAT AC50 for
peanut were IgE specific for peanut and the rAra h 1, 2, 3
and nAra h 6 components, along with the BAT AC50 for
soy (Fig. 2a).
Basophil activation test results for peanut-allergic versus
peanut-sensitized patients
The median BAT AC50 value obtained for peanut was sig-
nificantly higher for the PA-group at 6.84 (IQR 4.50) than
for the PS-group at 3.55 (IQR 4.15) (p < 0.001) (Fig. 3a). In
the PA-group, there were 3 (6 %) non-responders to pea-
nut and 5 (23 %) in the PS-group. No significant differ-
ences were noted comparing the median BAT values forbirch or soy between the two groups (Fig. 3b and c, re-
spectively). Basophils from healthy controls did not re-
spond to any of the allergens tested (Fig. 3a–c). The
gating strategy for the flow cytometry is presented in
Fig. 3d and e.
Does peanut BAT outcome correlate with other allergy
parameters in peanut-allergic patients?
In the PA-group, there was a positive correlation between
the BAT AC50 to peanut and BAT AC50 to soy (r = 0.413,
p = 0.004) but no correlation to the BAT AC50 for birch
(r= 0.161, p = 0.280). Interestingly, in this group, we found
a rather weak correlation between the BAT AC50 for
peanut and the levels of IgE directed against the individual
peanut components rAra h 1 (r = 0.314, p = 0.032), rAra h 2
(r= 0.291, p = 0.047), rAra h 3 (r = 0.289, p = 0.049), and
nAra h 6 (r = 0.347, p = 0.017), and surprisingly, no correl-
ation with the SPT or IgE level to peanut nor with total
serum IgE.
Basophil activation test to soy and birch in peanut
allergic vs peanut sensitized patients
In the PA-group, there were positive correlations be-
tween the BAT AC50 for soy and specific IgE to soy
(r = 0.585, p < 0.001), as well as specific IgE directed
against peanut (r = 0.584, p < 0.01). There was a similar
correlation to the individual component nGly m 6
(r = 0.583, p < 0.01) but a weaker correlation to nGly m
5 (r = 0.391, p < 0.01), as well as to the peanut compo-
nents rAra h 1 (r = 0.508 p < 0.001), rAra h 2 (r = 0.476,
p < 0.001), rAra h 3 (r = 0.661, p < 0.001), and nAra h 6
(r = 0.484, p = 0.001).
In the same group, we observed positive correlations
between the BAT AC50 for birch and r Bet v1
(r = 0.685, p < 0.01), SPT birch (r = 0.517, p < 0.01), IgE
birch (r = 0.657, p < 0.01), and rAra h 8 (r = 0.417,
p < 0.01).
In the PS-group, there were positive correlations be-
tween the BAT AC50 for peanut and the BAT AC50
for soy (r = 0.689, p < 0.01), but also the BAT AC50 for
birch (r = 0.735, p < 0.01). In this group, the BAT re-
activity to peanut correlated only with IgE to rAra h 8
(r = 0.479, p = 0.024) and rGly m 4 (r = 0.638, p = 0.01).





Fig. 3 The median BAT AC50-value (50 % of maximal basophil stimulation) for (a) peanut, (b) soy and (c) birch allergen extract in the basophil
activation test. PA, patients with severe peanut allergy; PS, peanut-sensitized patients; C, healthy controls. d-e Gating strategy for flow cytometry. d Basophils
are gated as SSC low and CD203c positive. e Using the negative control sample, a gate for non-stimulated basophils is set as CD63 low. Cells in
Q3 are considered to be non-activated basophils and cells in Q2 are considered to be activated basophils
Rentzos et al. Clinical and Translational Allergy  (2015) 5:22 Page 8 of 14found between the BAT AC50 for soy and the level of
IgE to peanut (r = 0.470, p = 0.027), as well as to the
soy component rGly m 4 (r = 0.447, p = 0.037).A complete list of the significant statistical correla-
tions observed between the studied variables in both
groups is provided in Additional file 1: Table S3 and
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group, respectively.Can BAT discriminate between peanut-allergic and
peanut-sensitized patients?
To determine a cut-off level for reactivity to peanut in
the BAT, so as to distinguish between the patients in
the PA-group and PS-group, ROC curves were applied.
They revealed that an optimal sensitivity of 79 % and a
specificity of 86 % could be obtained at a BAT AC50 of
5.27, which would allow the diagnosis of patients with
severe peanut allergy (AUC 0.862). With SPT to pea-
nuts, the highest sensitivity of 83 % and highest specifi-
city of 82 % were obtained for a wheal diameter of 3.5
(AUC 0.910), and the IgE to peanuts showed a sensitiv-
ity of 81 % and specificity of 91 % at an IgE level of
11.5 kU/L (AUC 0.922). The parameters that showed
the greatest power for distinguishing the two groups in
the ISAC assay were IgE to rAra h 2 [sensitivity of
91.5 % and specificity of 100 % at an IgE level of 0.75
ISU (AUC 0.957)], and nAra h 6 [sensitivity 100 % and
specificity 100 % at a level of 1.16 ISU(AUC 1.0)]
(Fig. 4).Fig. 4 ROC curve assessments of the sensitivity and specificity of the
basophil activation test for peanut (orange) (AUC = 0.862), SPT peanut
(blue) (AUC = 0.910), IgE peanut (green) (AUC = 0.922), rAra h 2 (red)
(AUC = 0.957), and nAra h 6 (purple) (AUC = 1.0)SPT and IgE reactivity
The SPT results, the median level of specific IgE and total
IgE for the different groups are presented in Additional
file 4: Table S2 and Additional file 5: Table S1. The median
wheal diameter in the SPT for peanut was 4+ and the me-
dian level of specific IgE for peanut was 64 kU/L (IQR 82)
in the PA-group, which was significantly higher than the
SPT for peanut at 2+ (p < 0.001) and median level of spe-
cific IgE at 2.45 kU/L (IQR 3.4) in the PS-group (p < 0.001)
(Additional file 5: Table S1 and Additional file 4: Table S2
and Fig. 5a). No significant differences were noted for total
IgE and IgE for soy when comparing the PA-group and PS-
group (Fig. 5b and d). However, the median level of specific
IgE for birch was significantly higher (p = 0.01) in the PS-
group at 25 kU/L (IQR 84.2) than in the PA-group at 6.1
kU/L (IQR 17.5) (Fig. 5c).
The median ISU values for the peanut components
rAra h 1 (30.6; IQR 46.5), rAra h 2 (10.8; IQR 23.2), rAra
h 3 (5.4; IQR 18.5), and nAra h 6 (23.6; IQR 41.1) in the
PA-group were significantly higher (p < 0.001 for each
component) than the corresponding values in the PS-
group (Fig. 6). The median ISU for the soy component
nGly m 6 1.6 ISU (IQR 8.5) was also significantly higher
in the PA-group (p = 0.03). However, in the PS-group,
the median ISU values for rAra h 8 (1.6; IQR 4,8), rBet
v 1 (25; IQR 34.5), and rGly m 4 (1.2; IQR 5.2) were sig-
nificantly higher (p = 0.01, p = 0.023 and p = 0.02, re-
spectively), as compared to the PA-group (Fig. 6). In
summary, the IgE reactivities for peanut and soy, indica-
tive of severe allergy, were found to be significantly
higher in the PA-group, whereas the levels of IgE anti-
bodies for peanut and soy, indicative of cross-reactivity
with birch pollen, were significantly higher in the PS-
group.
Frequency of IgE sensitization to allergen components
In the PA-group, all the patients were sensitized to nAra
h 6 and four of these patients were mono-sensitized to
nAra h 6, while one patient was sensitized to both nAra
h 6 and rAra h 8. All the remaining patients in the PA-
group were co-sensitized to rAra h 2 and at least one of
the other allergen components of peanut (rAra h 1, 3, 8).
In the PS-group, 15 patients were sensitized to Ara h 8,
one patient sensitized to both rAra h 3 and rAra h 8,
one patient was mono-sensitized to rAra h 9 and one
patient was sensitized only to nAra h 6 and rAra h 9. Six
patients were not sensitized to any of the peanut compo-
nents tested but tested positive for peanut in the SPT
and/or IgE assay (Table 2).
Discussion
In the present study, we show that BAT is useful as a
complementary tool for the diagnosis and evaluation of




Fig. 5 The median concentrations (kU/L) of specific IgE for (a) peanut, (b) soy and (c) birch and (d) the total IgE in patients with severe peanut
allergy compared to sensitized patients and controls. PA, patients with severe peanut allergy; PS, peanut-sensitized patients; C, healthy controls.
The Mann-Whitney test was used for the statistical comparisons
Rentzos et al. Clinical and Translational Allergy  (2015) 5:22 Page 10 of 14that basophil reactivity is significantly higher in patients
with a history of severe allergy to peanuts (PA), as com-
pared with peanut-sensitized (PS) patients; with a ROC
area under the curve of 0.862 and at a BAT AC50 value
of 5.27 the BAT shows a specificity of 86 % and a sensi-
tivity of 79 %. The BAT AC50 value of 5.27 corresponds
to a concentration of peanut antigen of 1.8 ng/ml being
used to stimulate the basophils. Interestingly, the BAT
AC50 value for the PA-group only weakly correlated
with the ISAC value for the peanut components rAra
h 1, rAra h 2, rAra h 3 and rAra h 6, which indicates
that these two tests complement each other. This sug-
gests that BAT can serve as a complementary diagnos-
tic tool to the conventional investigations with SPT
and specific IgE for patients with suspected severe
peanut allergy.
Recently, a study conducted by Santos et al. [24], in
which children with a history of anaphylaxis to peanut
were compared with peanut-sensitized children, showed
that the BAT could distinguish children with severepeanut allergy from children sensitized to peanuts with a
sensitivity of 97.6 % and a specificity of 96 % [24]. In that
study, the majority of the subjects underwent an open
challenge with peanut in addition to the BAT and con-
ventional allergy tests. These results are in the line with
the results of the present study. Other research groups
have also proposed the BAT as a diagnostic tool for pea-
nut allergy. Homsak et al. [28] reported that BAT re-
activity values were higher in children who experienced
severe reactions than in children with milder reactions.
Glaumann et al. [25, 29] showed that children who
reacted to peanuts in a DBPCFC had a higher BAT re-
activity than non-reactors. In the present study, none of
the patients with a history of anaphylaxis or very high
IgE titers was investigated with an open challenge, so
the previous results could not be confirmed [15, 16].
In recent years, the diagnostic options have expanded
with the use of allergen components. In all, six allergen
components for peanut allergy have been studied (rAra
h 1, rAra h 2, rAra h 3, nAra h 6, rAra h 8 and rAra h 9)
Fig. 6 The median of specific IgE against the allergen components rAra h 1, rAra h 2, rAra h 3, nAra h 6, rAra h 8, rAra h 9, rGly m 4, nGly m 5,
nGly m 6 and r Bet v 1 in patients with severe peanut allergy compared to sensitized patients and controls. PA, patients with severe peanut
allergy; PS, peanut-sensitized patients; C, healthy controls; ISU, ISAC Standard Units. * p < 0.05, ** p < 0.01. The Mann-Whitney U-test was used for
statistical comparisons of the different study groups
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formation is available regarding rAra h 9, which is the
predominant peanut allergen in Mediterranean regions
[30]. The importance of rAra h components for predict-
ing true peanut allergy is well documented in studies
conducted on children [31–34]. Accordingly, in the
present study, the patients who were diagnosed with se-
vere peanut allergy (PA) also showed significantly higher
levels of IgE to the peanut allergen components rAra h
1, rAra h 2, rAra h 3 and nAra h 6, as compared with
the peanut-sensitized patients (PS). However, recently it
was shown that, IgE to rAra h 2 was the best predictor
of clinical peanut allergy but rAra h 2 reactivity alone
could neither discriminate between mild or severe pea-
nut allergy nor could its absence exclude peanut allergyTable 2 IgE sensitization frequency to allergen components
(>0.35 ISU) between patients allergic to peanuts and patients
sensitized to peanuts. (PA peanut allergic patients, PS peanut
sensitized patients)
Peanut allergens components PA (n = 47) PS (n = 22)
rAra h 1 40 0
rAra h 2 43 0
rAra h 3 32 1
nAra h 6 47 1
rAra h 8 15 15
rAra h 9 0 2in an adult population [35]. It has been suggested that in
children, measurements of rAra h2 and nAra h 6 (as ho-
mologs) should be adequate as complementary tests [34],
while in the study of Bindeslev-Jensen et al. [36], which
was carried out in a mixed population of children and
adults, it was found that IgE reactivity to rAra h 2 yielded
a cut-off of 1.63 kU/L with a specificity of 100 % and sen-
sitivity of 70 %. IgE reactivities to these peanut compo-
nents have been proposed as a complementary test to
provide support for a diagnosis of suspected severe peanut
allergy [31–34]. However, when analyzing the reactivity
to birch we clearly see that peanut-sensitized, non-
anaphylactic patients (PS) show a significantly higher level
of specific IgE to birch, rBet v 1 and rAra h 8, as compared
with patients with severe peanut allergy, which indicates
that they are sensitized to peanut due to a cross-reaction
between birch pollen and peanuts [8].
In the multivariate factor analysis (SIMCA), we show
that SPT peanut, IgE to peanut, peanut components
(rAra h 1, rAra h 2, rAra h 3, nAra h 6), and the BAT
for peanut are all predictors of severe peanut allergy.
This is in contrast to the situation for the peanut-
sensitized patients, where the relevant parameters are
IgE to birch, rAra h 8 and rGly m 4, implying that these
patients suffer from birch-related, cross-reacting mild or
negligible symptoms.
It has been proposed that individuals with severe al-
lergy to peanut may develop a clinical sensitization to
Rentzos et al. Clinical and Translational Allergy  (2015) 5:22 Page 12 of 14legumes and vice versa, however there is little evidence
to support the notion that patients who are allergic to
peanut develop an allergy to soy because of the cross-
reactivity between the proteins in the two allergens
[11, 12]. On the other hand, patients who are allergic
to birch pollen may also develop a clinically low-grade
reactivity to soy protein due to cross-reactivity that
exists between rGly m 4 in soy and the major birch
pollen protein rBet v 1 [37–39]. For patients with severe re-
actions to soy, it has been suggested that they are sensitized
to the proteins nGly m 5 and nGly m 6 [40]. This is sup-
ported by the results obtained in the present study, in that
we observed that IgE directed against both nGly m 5 and
nGly m6 correlated with the BAT AC50 for soy, specific
IgE to soy extract and SPT to soy, which taken together
suggest a clinical allergy to soy in the PA-group. It is inter-
esting to note that the reactivities to nGly m 5 and nGly m
6 also correlated with the levels of specific IgE to peanut
and peanut recombinant allergens rAra h 1, rAra h 2, rAra
h 3 and nAra h 6 in the PA-group, which suggests that
sensitization to soy exerts an important clinical impact.
This may explain why patients with peanut allergy also
show adverse reactions to soy. In contrast, in the PS-group,
rGly m 4 correlated with the BAT AC50 for birch, specific
IgE for birch, rBet v 1 and rAra h 8, which can be attributed
to the co-existent allergy to birch pollen. rGly m 4 did not
correlate with the peanut components rAra h 1, rAra h 2,
rAra h 3 and nAra h 6 or with specific IgE to peanut, which
implies that reactivity to this component is not related to
true peanut allergy. In the PS-group, it is clear that rGly m
4 is correlated with specific IgE to birch, rAra h 8 and rBet
v 1, which confirms the data concerning cross-reactivity be-
tween birch pollen and this soy protein [39]. In addition,
our study clearly shows higher BAT AC50 values for soy in
the PA-group than in the PS-group, which supports the
idea that patients with severe allergy to peanut also have
developed a more severe allergy to soy.
Analysis of combinations of the BAT AC50P, IgE to pea-
nut, rAra h 1, rAra h 2, rAra h 3 and nAra h 6 by applying
logistic a regression analysis model revealed that any com-
bination of the different diagnostic tests does not improve
the accuracy of diagnosing severe peanut allergy (data not
shown). The use of the BAT before a food challenge has
already been suggested by Rubio et al., who observed a cor-
relation between basophil activation and the outcome of
oral food challenge before the re-introduction of cow milk
in allergic children [41]. It is worth mentioning that in one
patient from the PA-group who had high IgE titers to pea-
nut (92 kU/L) and near-maximal activation of basophils to
peanut (ten serial 10-fold dilutions), there were maximal
basophil responses to soy and birch (ten serial 10-fold dilu-
tions). Interestingly, this patient had low IgE titers for soy
(0.97 kU/L) and birch (0.55 kU/L), which implies that the
BAT may be a sensitive method for detecting potentialanaphylactic responses to allergens not identified by IgE re-
activity. This type of reactivity may explain some of the fatal
reactions to soy observed in peanut-allergic patients not di-
agnosed with soy allergy [42]. In this context, it should be
added that the BAT also seems to be highly sensitive and
specific for detecting traces of functionally active peanut al-
lergen even after the processing of peanut-containing food-
stuffs [43].
A relatively large proportion of the healthy controls
showed a low level of basophil activation to the positive
control, as compared with the allergic patients. This may be
explained by the fact that healthy controls have very low
total IgE levels, so their basophils are less sensitive to
stimulation with a cross-linking antibody to IgE and fMLP.
This observation is in line with previous data obtained
using the BAT for the diagnosis of food allergy in both aller-
gic patients and healthy controls where not all of the sub-
jects showed a clear basophil response when activated with
cross-linking antibodies to IgE [18]. Similar results were ob-
tained more recently in a study in which the BAT was eval-
uated in atopic and non-atopic subjects [44].
It is worth noting that the BAT is not influenced by
antihistamine medication [45], and there is currently no
evidence that ongoing treatment with inhaled steroids
influences the BAT outcome.
The high levels of sensitivity and specificity of the
BAT in identifying individuals with clinically important
IgE-mediated food allergy were confirmed in a previous
study in which patients allergic to birch with oral allergy
syndrome (OAS) to apple were compared with birch-
allergic patients without OAS to apple [46].
In the present study, it is shown that the BAT AC50
for peanut does not correlate with the levels of IgE to
the peanut allergen components, which suggests that the
BAT can identify patients who are allergic to peanuts
and who are not diagnosed with the conventional IgE-
tests. A combination of SPT, specific IgE, recombinant
allergens of peanuts and the BAT may be optimal for se-
curing an accurate diagnosis, as supported by a recent
report from Spain [47].
One limitation of the present study is that patients
with suspected severe allergy to peanut could not be in-
vestigated with an open challenge for ethical reasons.
Therefore, a correlation between the BAT outcome and
the present clinical anaphylactic status of patients is not
available.
As there are still very few studies investigating the
BAT as a diagnostic tool in adults with allergy to pea-
nuts, more studies are needed to establish its diagnostic
potential to predict severe reactions to peanuts.
Conclusions
BAT may be used as a complementary diagnostic tool to
ensure accurate diagnosis of severe peanut allergy in
Rentzos et al. Clinical and Translational Allergy  (2015) 5:22 Page 13 of 14adults. Further studies to correlate BAT reactivity with
the outcome of clinical challenge would be appropriate
to validate the BAT test as a tool to reduce the need for
open challenge in peanut allergic adults. Furthermore,
the BAT may be useful in revealing a hidden yet serious
allergy to soy in patients with peanut allergy.
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